|Podcasts|July 16, 2013
What does RBM mean to Sanofi's CRAs and site monitors
Lori Convy, Assistant Director, Clinical Research Monitoring, Sanofi discusses what risk-based monitoring mean to Sanofi's CRAs and site monitors?
Advertisement
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Life Sciences Can’t Afford Fragmented Data and Disconnected Teams
2
ACT Brief: Building a Digital Thread in Life Sciences, CRO Sourcing Decisions and Site Burden, and Lilly’s Oral GLP-1 Phase III Results
3
Applying AI to Automate Workflows Without Disrupting Sites
4
FDA Approves Subcutaneous Lunsumio VELO Based on GO29781 Trial Results in Relapsed or Refractory Follicular Lymphoma
5